Merck discontinues Phase 3 trial for lung cancer combo drug EP News Bureau Aug 9, 2024 When compared to patients in the control arm, patients in the vibostolimab and pembrolizumab fixed-dose combination arm…
Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC EP News Bureau Sep 11, 2023 IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with…
Roche gets positive CHMP opinion for Tecentriq plus Avastin to treat liver cancer EP News Bureau Sep 18, 2020 The recommendation from the CHMP is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in…
Roche gets US FDA approval for Tecentriq combo to treat advanced melanoma EP News Bureau Jul 31, 2020 The approval is based on results from the Phase III IMspire150 study, in which the addition of Tecentriq to Cotellic and Zelboraf…
Roche’s Atezolizumab receives DCGI approval for treatment of metastatic triple-negative breast… EP News Bureau Apr 8, 2020 Atezolizumbab is the first immunotherapy drug to be approved globally for treatment of unresectable locally advanced and…
Roche’s Atezolizumab receives DCGI approval for small cell lung cancer treatment in India EP News Bureau Nov 21, 2019 Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of ES-SCLC when given…